Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
Worldwide Spine Surgery: Products, Technologies, Markets & Opportunities, 2008-2017
2.
Worldwide Wound Management, 2007-2016: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World
3.
Worldwide Market for the Clinical Management of Obesity, 2007-2015
4.
Worldwide Surgical Sealants, Glues and Wound Closure Market, 2007-2011
5.
Emerging Trends, Technologies and Opportunities in the Markets for Orthopedic Biomaterials, Worldwide
6.
Ophthalmology Worldwide 2007: Products, Technologies, Markets and Opportunities in Ophthalmology Surgical, Diagnostic, Device and Drug Markets
7.
The Worldwide Market for In Vitro Diagnostic Tests, 6th Edition
8.
Blood-Brain Barrier: Bridging Options for Drug Discovery and Development
9.
Cardiotoxicity: Issues, Technologies, and Solutions for the Future
10.
Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
Best Sellers:
1.
AMD Market Outlook to 2012
2.
The Commercial Success of Cancer Therapeutic Antibodies
3.
Breast Cancer Therapeutics and Competitive Insights
4.
BioNewsCast Press Release Distribution Service
5.
Pharmaceutical Market Trends, 2007 - 2011
6.
21 CFR Part 11 course
7.
Distribution Agreements in Biopharma
8.
Decoding Big Pharmas R&D Strategy in Oncology
9.
Asthma Therapeutics: New treatment options and emerging drug discovery targets
10.
Advertising on BioPortfolio
Bigpharma Agreements Handbook 2007
Summary
The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.
Description
Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.
Understanding the flexibility of a prospective partners negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.
Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.
The initial chapters of this report provide an orientation of bigpharmas dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.
The main body of the report is provided in chapter 5. Each of the top 50 bigpharma companies is provided with a brief summary followed by a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.
Report scope
Bigpharma Agreements Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a companys approach to partnering.
Bigpharma Agreements Handbook 2007 includes:
The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
Detailed partnering activity and interests profiles for the leading fifty bigpharma companies
Listing of over 1,000 contract documents between bigpharma and partner companies
The leading M&A and partnering deals by value 2005-6
Most active M&A and partnering dealmakers 2005-6
The leading partnering resources
For each company in Bigpharma Agreements Handbook 2007, the available contracts are listed by deal type, including:
Co-development
Co-marketing
Co-promotion
Collaborative R&D
Development
Distribution
Joint venture
Licensing
M&A
Manufacturing
Marketing
Promotion
Research
Supply
Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.
The Bigpharma Agreements Handbook 2007 provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Date of publication: September 2007 Total pages: 310 Publisher: CurrentPartnering Format: PDF
Table of Contents
Price: $2,195.00 / GBP1,097.50
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.